ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
about
Interventions for the treatment of oral and oropharyngeal cancers: immunotherapy/biotherapyA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyVandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport functionMET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC CellsAnti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agentsAssessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude ratTargeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoVascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.Cellular responses to EGFR inhibitors and their relevance to cancer therapy.Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyImmunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancerMolecular biology of epidermal growth factor receptor inhibition for cancer therapy.ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.Current approaches to medullary thyroid carcinoma, sporadic and familial.Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer.Advances in experimental and translational research in the treatment of hepatocellular carcinomaThe antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissuesImpact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Vandetanib: in medullary thyroid cancer.Vandetanib: a guide to its use in advanced medullary thyroid cancer.Vandetanib for the treatment of medullary thyroid carcinoma.Renal effects of targeted anticancer therapies.Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapySelective use of vandetanib in the treatment of thyroid cancer.Cordycepin Induces Apoptosis and Inhibits Proliferation of Human Lung Cancer Cell Line H1975 via Inhibiting the Phosphorylation of EGFR.Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor.Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines.Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization.Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanibApplication of radiotherapy and chemotherapy protocols to pre-clinical tumor models.
P2860
Q24202546-91017E8C-EC55-4F16-8FB2-5015DD298EF9Q26824462-888281CB-8BB7-42CF-ACB9-434AE13BCC78Q28475378-700564FD-1265-4B41-8891-A5891FEBB6F0Q28551045-7FE07F26-5D96-4683-A0A3-46223F53A869Q30388655-4C4F9C72-29B4-4EFA-B0BA-C7071F66BA86Q33786788-4D68059A-4D22-480E-AEBC-32881FA80846Q33872751-BA89C49D-8D3A-4D22-AD84-0421ABC7DB95Q34105344-4F4197C0-4613-420A-9B75-76A49E00987FQ34217687-5F513256-3FBD-405E-9264-5F2CDD5F3597Q34250003-DACFFF6A-342A-47AB-B9CD-1315934CA94AQ34773458-EBB3EFBF-B32E-4A5D-9CF6-7D8C4B3DD1ABQ34787422-7723F5DF-508C-42EA-A498-DBAC52709798Q35163198-BDE5EC65-5336-4AE8-AFAB-6ACB8381DDECQ35396089-7C016FA9-5C2E-44B4-B056-E2707F5E1A3FQ36003118-D7AE20A7-79AF-44CC-888A-6B24A5085E60Q36101895-6AC48C8A-D845-413C-9F61-A446822B6130Q36116250-06183FE9-BE5A-4878-B183-BB0383AE9165Q36388489-19E4BABF-940E-4FAB-A5A8-078644ADA068Q36481002-25EF0A5D-AE8D-45B8-95C3-DC4EA2E665C6Q36611278-6A91080B-30EC-4434-B388-4862BA813D84Q36613969-E66609E5-93BA-4D7F-8EF4-97C09C0E50AFQ36666674-D73A5436-9445-4EFD-908C-6C5731C929F1Q36715777-CFB0EED6-8753-4B47-9863-AE83AE8F4E35Q36764012-58D973CC-E2C4-43E5-AEC2-98B64959FFA4Q37122717-9DF6E214-0F5B-4581-B792-504A296AD79EQ37287554-A5C8E0D8-DC52-4127-9D3F-C35B337C44D8Q37451272-41285E67-218F-4AF3-ABC6-EDED7F565D3FQ38020194-48CDDD08-D34B-432E-BF3E-5A44B35967C6Q38039483-55224FD5-7CC4-439E-A1AA-73D5E788F954Q38164676-1CC45A9C-0321-468D-AEF7-A21BA63E9CA9Q38367168-2686DCE2-A008-4DEA-85E6-F1A947F6778CQ38389986-FC3B1D1E-DB2A-476E-84C5-B8AA305532ADQ38546474-607E24C2-A99C-4C6C-9849-E6BBBCF6441BQ38743023-94A0D4FE-2698-4E5D-BE42-476D0EBA91E0Q39018134-F0F0A556-98E7-44B3-9BE9-945314C7CA7FQ39187613-8CECAB83-D806-4205-B708-8EC3028105CCQ39489171-DC08DCAF-24F1-4537-88CE-3592F492FCB6Q40980345-E16768C6-8931-4B84-AC8B-2C3B3337B11DQ41956993-82B490CB-BCDF-407A-9E86-57D2AE359E8AQ42726590-020D5191-987B-4E9D-9228-A41DF6030591
P2860
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
@ast
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
@en
type
label
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
@ast
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
@en
prefLabel
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
@ast
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
@en
P2860
P356
P1476
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
@en
P2093
P2860
P2888
P356
10.1038/SJ.BJC.6602603
P407
P478
92 Suppl 1
P577
2005-06-01T00:00:00Z
P5875
P6179
1047578681